NCT00170911View on ClinicalTrials.gov

Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

December 31, 2005

Conditions
Osteoporosis
Interventions
DRUG

AAE581

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY